PTCT · Ptc Therapeutics, Inc.
$71.70
-0.27 (-0.38%)
At close · Aug 14
Market Cap
$5.98B
Shares
83.46M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$71.70
Open$71.58
Day$70.85–72.13
52W close$48.70–89.55
Avg vol 30d1.3M
Short int10.6M · 12.7% float · 7.5d
Short vol67%
Last earningsJul 30, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 30
Up next
Next earnings call
Oct 20, 2026
Est · unconfirmed
· in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 30, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Moderate
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−2%
below
Price vs 50-day avg
−7%
below
RSI (14)
41
neutral
MACD trend
Positive
52-week position
56%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−9%
trailing
6-month return
+2%
trailing
YTD return
−6%
this year
Relative strength
−12%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $77 › 200d $73 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +74 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.66% of float · ▲ +7.4% MoM · 7.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
376 holders — near 3-yr high, broad support
Squeeze score
66
elevated · 0–100
Fundamentals
Revenue growth
+36%
Y/Y
EPS growth
+264%
Y/Y
Free cash flow
$702.3M
Balance sheet
$412.6M
net cash
Quant / Vol
risk profile
Volatility
41%
annualized · 1-yr
Max drawdown
−27%
past year
ATR
3.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 30, 2026
Total revenue
· Full-year 2026
$1.18B – $1.28B
Product revenue
· Full-year 2026
$850M – $950M
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
2025 full-year revenue
· 2025 full-year
$750M – $800M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−2%
Neutral
Price vs 50-day avg
−7%
Bearish
RSI (14)
41
Neutral
MACD trend
Positive
Bullish
52-week position
56%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $77 › 200d $73 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +74 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.66% of float · ▲ +7.4% MoM · 7.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
376 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $49
Now $72 · 56%
Range high $90
vs 200-day avg -2%
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP R&D expenses non-GAAP | $88.6M | Q2 2026 | — |
|
|
|||
| Non-GAAP SG&A expenses non-GAAP | $67.9M | Q2 2026 | — |
|
|
|||
| Patients on commercial therapy worldwide | 1,647 | Q2 2026 | — |
| Total patients on commercial therapy worldwide | 1,244 | Q1 2026 | — |
| Patient start forms received in the US | 1,134 | as of December 31, 2025 | — |
| Sephience Q4 2025 ex-US net revenue | $11M | Q4 2025 | — |
| Sephience Q4 2025 net revenue | $92M | Q4 2025 | — |
| Sephience Q4 2025 US net revenue | $81M | Q4 2025 | — |
| Sephience total net revenue since launch | $111M | since launch in 2025 | — |
| Cash, cash equivalents, and marketable securities | $1.94B | as of December 31, 2025 | — |
| Sephience US Q4 2025 net revenue | $81.6M | Q4 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PTCT
this stock
Ptc Therapeutics, Inc.
|
$5.98B | -5.6% | +36.2% | — | 12.7% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PTCT | -2.2% | -8.8% | +1.7% | +5.4% | -5.6% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -2.6% | -13.2% | -12.1% | +1.5% | -19.5% |
Key facts
CIK
1070081
CUSIP
69366J200
13F (30d)
377 filings
348 filers
Visit website
Investor relations